Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00403052 · ClinicalTrials.gov registry record · Phase 1
A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Dynavax Technologies Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00403052 is a Phase 1 study that was terminated before completion, run by Dynavax Technologies Corporation. The registered enrollment target is 14 participants.
The verdict
NCT00403052, a Phase 1 study, was terminated before completion, sponsored by Dynavax Technologies Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The main objectives of this study are to establish a safe, tolerable and active dose of 1018 ISS administered in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer. Other objectives also include determining tumor response, time to disease progression, and overall survival in treated patients.
Interventions
- DRUG 1018 ISS immunostimulatory oligonucleotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00403052
The ClinicalTrials.gov registry entry for NCT00403052 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dynavax Technologies Corporation, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 1018 ISS immunostimulatory oligonucleotide is the first listed.
NCT00403052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00403052 about?
NCT00403052 is a clinical study titled "A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer". The main objectives of this study are to establish a safe, tolerable and active dose of 1018 ISS administered in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer. Other objectives also include determining tumor response, time to disease progression, and overall...
What is the current status of trial NCT00403052?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2006-11. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00403052?
The interventions under investigation include: 1018 ISS immunostimulatory oligonucleotide (DRUG).
Who is sponsoring clinical trial NCT00403052?
This trial is sponsored by Dynavax Technologies Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.